Star-D: Lessons learned and future implications

Depression and Anxiety

Volumn 28, Issue 7, 2011, Pages 521-524

  Rush, A John ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; FLUOXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DISEASE COURSE; FOLLOW UP; FUTUROLOGY; HEALTH SURVEY; HUMAN; LEARNING; MENTAL HEALTH CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CONTROLLED CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; PATIENT SELECTION; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 79960016570     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20841     Document Type: Article

References (30)

1. Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs 2009; 23: 627-647.
2. Shern DL, Moran H,. STAR*D: helping to close the gap between science and practice. Psych Serv 2009; 6: 1458-1459.
3. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ,. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009; 60: 1439-1445.
4. Laje G, Perlis RH, Rush AJ, McMahon FJ,. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv 2009; 60: 1446-1457.
5. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009; 166: 599-607.
6. Rush AJ, Trivedi MH, Wisniewski SR, et al., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917. (Pubitemid 44807782)
7. Kwan P, Brodie MJ,. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319. (Pubitemid 30075244)
8. Diazgranados N, Ibrahim LA, Brutsche NA, et al. Rapid resolution of suicidal ideation after a single infusion of an N-
9. Murrough JW, Charney DS,. Cracking the moody brain: lifting the mood with ketamine. Nat Med 2010; 16: 1384-1385.
10. Price RB, Nock MK, Charney DS, Matthew SJ,. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66: 552-556.
11. Okamoto N, Nakai T, Sakamoto K, Nagafusa Y, Higuchi T, Nishikawa T,. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression. J ECT 2010; 26: 223-227.
12. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methly-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864. (Pubitemid 44188478)
13. Fava M, Mischoulon D,. Folate in depression: efficacy, safety differences in formulations, and clinical issues. J Clin Psychiatry 2009; 70: 12-17.
14. Stahl SM,. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr 2007; 12: 744-793.
15. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF,. Major depressive subtypes and treatment response. Biol Psychiatry 1997; 42: 568-576. (Pubitemid 27425475)
16. Flint AJ, Rifat SL,. Anxious depression in elderly patients. Response to antidepressant treatment. Am J Geriatr Psychiatry 1997a; 5: 107-115. (Pubitemid 27157394)
17. Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D,. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety 2002; 16: 4-13. (Pubitemid 34977120)
18. Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004; 34: 1299-1308. (Pubitemid 39517160)
19. Tollefson GD, Holman SL, Sayler ME, Potvin JH,. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994; 55: 50-59. (Pubitemid 24081821)
20. Russell JM, Koran LM, Rush AJ, et al., Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001; 13: 18-27. (Pubitemid 32537090)
21. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165: 342-351. (Pubitemid 351704490)
22. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies. Predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008; 65: 870-881.
23. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40. (Pubitemid 43050100)
24. Quitkin MF, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 2003; 160: 4.
25. Lesser IM, Leuchter AF, Trivedi MH, et al. Characteristics of insured and non-insured depressed outpatients: preliminary findings from STAR*D. Psychiatr Serv 2005; 56: 995-1004. (Pubitemid 41098740)
26. Lesser IM, Leuchter AF, Trivedi MH, et al. Insured and non-insured depressed outpatients: how do they compare? Ann Clin Psychiatry 2007; 19: 73-82. (Pubitemid 47035943)
27. Davis LL, Rush AJ, Wisniewski SR, et al., Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the STAR*D cohort. Compr Psychiatry 2005; 46: 81-89. (Pubitemid 40249874)
28. Wickramaratne P, Gameroff MJ, Pilowsky DJ, et al. Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child Study. Am J Psychiatry 2011; 168: 1-10.
29. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 2006; 59: 493-501. (Pubitemid 43320536)
30. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA,. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatry Pract 2006; 12: 71-79. (Pubitemid 44284089)